Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype

Completed · Phase 2 · Has a placebo group

Conditions studied: Alpha1-Antitrypsin Deficiency

In brief

This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-864 in PiZZ subjects.

Key facts

Study ID
NCT04474197
Run by
Vertex Pharmaceuticals Incorporated
People needed
44
Starts
2020-07-24
Expected to finish
2021-05-04
Last updated by the study team
2022-05-26

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.